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STAT3 regulated ARF expression suppresses
prostate cancer metastasis
Jan Pencik1, Michaela Schlederer1,2, Wolfgang Gruber3, Christine Unger4, Steven M. Walker5, Athena Chalaris6,
Isabelle J. Marie´7,8, Melanie R. Hassler2, Tahereh Javaheri1, Osman Aksoy2, Jaine K. Blayney9, Nicole Prutsch2,
Anna Skucha10, Merima Herac2, Oliver H. Kra¨mer11, Peter Mazal2, Florian Grebien1, Gerda Egger2, Valeria Poli12,
Wolfgang Mikulits13, Robert Eferl13, Harald Esterbauer14, Richard Kennedy5, Falko Fend15, Marcus Scharpf15,
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Martin Susani2, Ali Moazzami18, Stefan Rose-John6, Fritz Aberger3, Olaf Merkel2, Richard Moriggl1,19,
Zoran Culig20, Helmut Dolznig4 & Lukas Kenner1,2,21
Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to
be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to
provide therapeutic beneﬁt. Here we show that genetic inactivation of Stat3 or IL-6 signalling
in a Pten-deﬁcient PCa mouse model accelerates cancer progression leading to metastasis.
Mechanistically, we identify p19ARF as a direct Stat3 target. Loss of Stat3 signalling disrupts
the ARF–Mdm2–p53 tumour suppressor axis bypassing senescence. Strikingly, we also
identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions
co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14ARF
expression in patient tumours correlates with increased risk of disease recurrence and
metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low
risk PCa patients. Our ﬁndings challenge the current discussion on therapeutic beneﬁt or risk
of IL-6/STAT3 inhibition.
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P
Ca is the second most frequently diagnosed cancer in men
with 4200,000 new cases reported in the USA annually1.
Screening for the sensitive yet diagnostically unspeciﬁc
biomarker prostate-speciﬁc antigen (PSA) has led to a substantial
rise in the diagnosis of early stage PCa2. The failure of
current diagnostic tools to reliably distinguish non-aggressive
tumours from aggressive ones to predict therapeutic response3
urgently calls for the identiﬁcation of better biomarkers to guide
treatment. Furthermore, there is need for novel targeted therapies
of metastatic PCa based on a better molecular understanding
of the disease4. The lack of markers to stratify PCa cases into
low- and high-risk groups results in overtreatment of 20–42%
of patients5. STAT3, the major downstream mediator of IL-6
signalling, was shown to be related to advanced tumour growth,
by tumour-autonomous mechanisms and by modulating
tumour-associated stroma6. Although STAT3 activation is
observed in B50% of PCa7 its functional role in tumorigenesis
and metastasis has not been elucidated. Data from the majority of
human PCa cancer cell lines support an oncogenic and growth
promoting role of IL-6 and STAT3 in vitro8. However, metastatic
LNCaP cells were growth inhibited in vitro and in vivo in
response to IL-6 treatment8. Moreover, treatment of patients with
an IL-6 blocking antibody did not result in a survival advantage in
patients with advanced PCa9. Thus, addressing the precise in vivo
role of IL-6/STAT3 in PCa is of utmost importance to reassess
diagnostic and therapeutic approaches.
PTEN is one of the most frequently deleted or mutated tumour
suppressors in PCa, with an estimated incidence of 70%
in metastatic PCa, causing aberrant activation of the PI3K–
AKT–mTOR signalling pathway10. Loss of Pten leads to
senescence, which is critically regulated by the ARF–p53
pathway11. While the tumour suppressor ARF (p14ARF in
humans; p19ARF in mice) is readily degraded in normal cells,
it is stabilized to increase p53 function on loss of Pten. ARF was
shown to augment p53 stability by promoting the degradation
of Mdm2, a negative regulator of p53. Concomitant inactivation
of Pten and p53 leads to bypass of senescence and as a
consequence to a malignant PCa phenotype11. Previous studies
report PTEN–STAT3 signalling crosstalk in malignant
glioblastoma12, but the detailed molecular mechanisms in
cancer progression and metastasis remain unresolved.
In this study, we show that loss of IL-6/Stat3 signalling in a
Pten-deﬁcient PCa model accelerates cancer progression leading to
metastasis. Loss of IL-6/Stat3 signalling in PCa bypasses senescence
via disrupting the ARF–Mdm2–p53 tumour suppressor axis. We
identify ARF as a novel direct Stat3 target. Notably, loss of STAT3
and p14ARF expression correlates with increased risk of recurrence
in PCa patients. In addition, STAT3 and p14ARF expression was
lost in metastasis compared with the primary tumours. We
identiﬁed STAT3 and CDKN2Amutations in primary PCa patients.
Furthermore, PCa metastases show a high frequency of STAT3 and
CDKN2A deletions. We propose STAT3 and ARF as prognostic
markers for high versus low risk PCa patient stratiﬁcation.
Results
Co-deletion of Stat3 and Pten triggers PCa. To study the role
of PTEN and STAT3 in PCa development, we took advantage
of mice with conditional loss of Pten in the prostate epithelium
(Pb-Cre4 Ptenﬂ/ﬂ) hereafter referred to as Ptenpc / (ref. 13).
Stat3 protein levels were markedly induced in Ptenpc /
compared with wild-type (WT) prostate epithelium (Fig. 1a,b).
Ptenpc / tumours showed strong Akt Ser473 phosphorylation
and, unexpectedly, Stat3 Tyr705 and Ser727 phosphorylation
suggesting maximal transcriptional activity of Stat3 (Fig. 1a,b and
Supplementary Fig. 1a). In addition, we observed an increase in
IL-6Ra levels in tumour cells and soluble IL-6R serum levels
(Supplementary Fig. 1a–c) as well as increased Stat3, IL-6Ra and
IL-6 mRNA levels (Supplementary Fig. 1d) in Ptenpc / PCa
compared with WT controls. To prove that loss of Stat3
signalling inﬂuences PCa formation, we generated mice with
concomitant loss of Pten and Stat3 in prostate epithelial cells.
Prostate-speciﬁc deletion of Pten and Stat3 was conﬁrmed
by PCR (Supplementary Fig. 2a). Immunohistochemistry
(IHC) analysis conﬁrmed loss of pY-Stat3 and Stat3 in
Ptenpc /Stat3pc / tumour cells (Supplementary Fig. 2b),
while still being present in stromal cells (Supplementary Fig. 2c).
Surprisingly, and in sharp contrast to the oncogenic role of
Stat3 in many cancers14,15, Ptenpc / Stat3pc / mice showed
accelerated PCa formation with up to sixfold increase in tumour
weight compared with Ptenpc / tumours at different stages of
PCa development (Fig. 1c,d and Supplementary Fig. 2d,e).
Ptenpc / Stat3pc / tumours showed increased numbers
of Ki-67 positive (Ki-67þ ) proliferating cells and reduced
numbers of cleaved caspase 3 positive (CC3þ ) apoptotic cells
compared with Ptenpc / prostates (Fig. 1e,f).
Compared with Ptenpc / mice16, Ptenpc /Stat3pc /
mice displayed a signiﬁcantly reduced median survival (Fig. 1g).
Intriguingly, Ptenpc /Stat3pc / mice developed high-grade
(poorly differentiated) PCa with liver and lung metastases
(Fig. 2a). Histopathological analysis of PCa-bearing animals
revealed widespread metastasis in 75% of Ptenpc /Stat3pc /
mice. By contrast, Ptenpc / mice only showed local invasion
into seminal vesicles and never developed distant metastases
(Fig. 2b and Supplementary Table 1). Furthermore, loss of Stat3
promoted PCa formation in Pten heterozygous prostate tissue
(Ptenpcþ / Stat3pc / ) at 19 weeks of age, whereas Ptenpcþ /
mice developed only prostatic intraepithelial neoplasia17 (PIN)
(Supplementary Fig. 3a). Our data demonstrate that Stat3
suppresses malignant progression of Pten-deﬁcient PCa. We
found reduced p53 protein expression in Ptenpcþ /Stat3pc /
prostates (Supplementary Fig. 3b). Pten heterozygosity alone had
no effect on p53 expression as demonstrated before11.
Interestingly, prostate-speciﬁc loss of Stat3 (Stat3pc / ) led to
development of PIN lesions in prostates at 19 weeks of age
(Supplementary Fig. 3c). Analysis of consecutive sections revealed
invasive regions and high-grade PIN in Ptenpc / mice at 19
weeks of age, whereas Ptenpc /Stat3pc / mice showed early
progression to poorly differentiated adenocarcinoma (Fig. 2c). At
52 weeks of age Ptenpc / Stat3pc / tumours had developed
into poorly differentiated carcinomas with 86% penetrance
compared with Ptenpc / tumours, which showed only signs
of focal invasion and late adenocarcinoma formation (Fig. 2d).
Notably, Ptenpc / tumour cells uniformly expressed nuclear
Stat3 at 19 weeks of age (Fig. 2e), whereas more advanced
tumours at 52 weeks of age showed profoundly reduced nuclear
Stat3 expression (Fig. 2e,f), suggesting that Stat3 expression
decreased during PCa progression.
To further dissect the tumour promoting effects of loss of Stat3,
we established primary mouse Pten / PCa cells with stable,
short hairpin RNA (shRNA) mediated knockdown of
Stat3. Western blot and IHC analyses conﬁrmed efﬁcient Stat3
knockdown in these cells (Fig. 3a and Supplementary Fig. 4a). In
line with our genetic data, Pten / mouse PCa cells with shStat3
knockdown were signiﬁcantly more invasive in a transwell
invasion assay compared with control cells (Fig. 3b). We veriﬁed
the aggressive behaviour of PTEN–STAT3 double deﬁcient
tumour cells in an organotypic, physiologically relevant in vitro
three-dimensional cancer model18. Pten / -shStat3 PCa
cells displayed a more invasive phenotype compared with
control cells in organotypic assays (Fig. 3c and Supplementary
Fig. 4b). In addition, Pten / -shStat3 cells showed increased
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anchorage-independent cell growth in soft agar compared with
Pten / PCa cells expressing non-targeting shRNA (control
shRNA) (Fig. 3d). To corroborate our ﬁndings in human cells,
combined knockdown of STAT3 and PTEN in human RWPE-1
prostate cells (Fig. 3e) increased invasiveness in organotypic assay
compared with control and single knockdown cells (Fig. 3f,g).
Notably, re-expression of STAT3 in human PC3 prostate
carcinoma cells, which lack STAT3 expression (Supplementary
Fig. 4c), led to signiﬁcantly decreased cell numbers and reduced
foci formation (Fig. 3h and Supplementary Fig. 4d,e). These data
are consistent with a cell-autonomous tumour suppressive role of
Stat3 in PCa.
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Figure 1 | Genetic deletion of Stat3 and Pten triggers progressive prostate tumorigenesis and lethal disease. (a) Comparison of prostates from WT
and Ptenpc / mice at 19 weeks of age using immunohistochemical (IHC) analysis of pY-Stat3, pS-Stat3 and Stat3. Scale bars, 100mm. (b) Protein
expression analysis of pY-Stat3, pS-Stat3, Stat3, p-Akt, Akt and b-actin with western blots in 19-week-old prostates from WT and Ptenpc / mice.
(c) Gross anatomy of representative prostates isolated at 52 weeks of age from WT, Stat3pc / , Ptenpc / and Ptenpc /Stat3pc / mice. Scale bars,
10mm. (d) Prostate weights of 52-week-old WT, Stat3pc / , Ptenpc / and Ptenpc /Stat3pc / mice (n¼ 24). Mean values are shown; Data were
analysed by one-way analysis of variance with Tukey’s multiple comparison test; error bars: s.d. (e) IHC analyses of prostates from 19-week-old WT,
Stat3pc / , Ptenpc / and Ptenpc /Stat3pc / mice stained for Ki-67 and cleaved caspase 3 (CC3). Scale bars, 100 mm; insets:  600 magniﬁcation.
(f) Quantiﬁcation of cells positive for Ki-67 and CC3 using HistoQuest software (n¼ 5). Data were analysed by Student’s t-test and are shown as
mean±s.d. (g) Kaplan–Meier cumulative survival analysis revealed a signiﬁcant (Po0.0001; log-rank test) decrease in lifespan of Ptenpc /Stat3pc /
compared with Ptenpc / mice (n¼49); WT and Stat3pc / mice served as controls.
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Stat3 regulates the ARF–Mdm2–p53pathway. Since loss of Pten
triggers senescence thereby restricting cancer progression and
metastasis11, we next tested whether Stat3 exerts a tumour
suppressive function by activating senescence-inducing
programmes in Ptenpc /PCa cells19 at an early stage of
PCa development (19 weeks). Senescence is generally
characterized by upregulation of p53, cyclin-dependent kinase
inhibitor 1 (Cdkn1, p21), promyelocytic leukaemia protein (PML)
and elevated senescence-associated-b-galactosidase activity20.
Of note, Ptenpc /Stat3 / tumours lacked p21 expression,
displayed reduced numbers of PML nuclear bodies and decreased
SA-b-Gal activity compared with Ptenpc / tumours (Fig. 4a,b
and Supplementary Fig. 5a,b), suggesting Stat3 as a novel
mediator of senescence in response to loss of Pten.
Senescence associated with loss of Pten was shown to be
bypassed by deletion of p53 leading to early lethality11. We
show here that loss of Stat3 and Pten revealed a phenotype
strikingly similar to that of p53 and Pten loss11. Intriguingly,
Stat3 and Pten deletion resulted in downregulation of p53
expression in the prostate epithelium, which was accompanied
by the loss of p19ARF (Fig. 4a,b). The p53 expression in the
tumour stromal cells remained unchanged (Supplementary
Fig. 5c). Since p19ARF is a critical regulator of Mdm2
degradation21, our results suggest that the tumour suppressive
capacity of Stat3 in senescent tumour cells22 may rely on the
p19ARF–Mdm2–p53 tumour suppressor axis.
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Figure 2 | Co-deletion of Stat3 and Pten enhances prostate cancer transformation and metastatic potential. (a) Histopathological analysis of primary
PCa, livers and lungs at 52 weeks of age from WT, Ptenpc / and Ptenpc /Stat3pc / mice. The dashed red lines encircle areas of advanced
liver or lung metastases (M), which are surrounded by normal liver (Li) or normal lung (Lu), respectively. Scale bars, 100mm; insets: 600 magniﬁcation.
(b) Percentage of mice with sites of distant PCa metastases (n¼49). (c) Summary of the histological ﬁndings of mouse prostates examined at 19 weeks
postpartum (p.p.) from WT, Stat3pc / , Ptenpc / and Ptenpc /Stat3pc / mice. (d) Summary of the histological ﬁndings of mouse prostates
examined at 52 weeks p.p. from WT, Stat3pc / , Ptenpc / and Ptenpc /Stat3pc / mice. Histological grading and classiﬁcation of mouse prostates
was done according to Chen et al.67 (e) Stat3 IHC in 19-week- and 52-week-old Ptenpc / prostate tumours. Scale bars, 100mm. (f) Quantiﬁcation of
Stat3 staining in 19-week- and 52-week-old Ptenpc / prostate tumours using HistoQuest software, Po0.0001. Data were analysed by Student’s t-test
and are shown as mean±s.d. (n¼ 5).
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Recently, co-inactivation of p53 and ARF was linked to human
triple-negative breast cancer progression through IFNb–
STAT1–ISG15 signalling23. Interestingly, ISG15 and Stat3
protein expression levels paralleled each other in the PCa
mouse models (Supplementary Fig. 6a). This suggests an altered
ISGylation system, which could be independent of androgen
receptor expression24 (Supplementary Fig. 6b). It is noteworthy,
that numerous AR-positive tumour cells were observed in
the metastases of the Ptenpc /Stat3pc / PCa mouse
models (Supplementary Fig. 6c), underlining the relevance
of our model to human PCa25. Molecular pathological
analysis conﬁrmed AR-positive tumour nodules in ﬁve out of
ﬁve cases of lung metastases consist of 66% AR-positive cells
(Supplementary Fig. 6d).
Mechanistically, Pten was shown to block PI3K-mediated
translocation of Mdm2 into the nucleus, where it promotes rapid
degradation of p53 (ref. 26). In line with the published function of
PML to increase p53 stability by sequestering Mdm2 to the
nucleolus, disruption of Pten and Stat3 resulted in increased
Mdm2 protein levels (Fig. 4b). Therefore, loss of Stat3 promotes
PCa development by bypassing senescence regulated by the
p19ARF–p53 axis. We therefore hypothesize that Stat3 may act
through ARF as an important gatekeeper controlling senescence
counteracting metastasis, which we tested further.
Immunoblot and IHC analyses revealed a positive correlation
between Stat3 and p19ARF levels. Moreover, loss of Stat3 led to a
profound decrease in p19ARF protein (Fig. 4a,b). Transcript levels
of the well-established Stat3 target genes Socs3 and c-fos27
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paralleled p19ARF expression in WT, Ptenpc / and
Ptenpc / Stat3pc / prostate tissue (Supplementary
Fig. 7a,b). Stat3pc / prostates displayed a signiﬁcant decrease
in p19ARF protein and mRNA levels compared with WT controls
(Fig. 4c,d), suggesting direct regulation of p19ARF expression by
Stat3. We ﬁrst tested this by analysing p19ARF expression in
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passage-matched homozygous Stat3 knockout (Stat3KO) and WT
mouse embryonic ﬁbroblasts (MEFs). Both p19ARF protein and
mRNA levels were signiﬁcantly reduced in the absence of Stat3
(Supplementary Fig. 7c,d). Consistently, MEFs expressing one or
two hyperactive Stat3 alleles (Stat3C/þ and Stat3C/C) from the
endogenous Stat3 locus28 displayed upregulation of p19ARF protein
and mRNA (Fig. 4e,f). In silico analysis of the p19ARF promoter29
predicted two potential Stat3-binding sites (Supplementary
Fig. 7e). Chromatin immunoprecipitation (ChIP) experiments
showed approximately threefold increase in Stat3-binding activity
to the proximal p19ARF promoter region in WT compared with
Stat3pc / prostate tissue (Fig. 4g). We next wanted to know if
Stat3 binding was further elevated in Pten-deﬁcient tumours since
Pten loss increased ARF expression. By performing ChIP in
Ptenpc / primary mouse prostate tumours, we demonstrated a
15-fold increase of Stat3 binding to the p19ARF promoter (Fig. 4h),
which was abrogated in Ptenpc /Stat3pc / tumours. These
data identify p19ARF as a novel Stat3 target gene.
Loss of IL-6 and Pten leads to cancer and metastasis. IL-6 sig-
nalling is the major regulator of Stat3 with therapeutic relevance.
To address whether Stat3 activation in Ptenpc / mice depends on
IL-6 signalling, we crossed Ptenpc / mice with IL-6 / mice30.
Co-deletion of IL-6 and Pten triggered early lethality (Fig. 5a),
progressive high-grade adenocarcinoma formation with increased
tumour growth and weight (Fig. 5b,c), resulting in disseminated
metastases (Fig. 5d), for example, in the liver (Supplementary
Fig. 8a). Loss of IL-6 in Pten heterozygous prostate tissue
also resulted in high-grade invasive PCa with metastasis
formation at 15 months of age (Supplementary Fig. 8b). Like
Ptenpc / Stat3pc / mice, Ptenpc / IL-6 / mice showed
markedly enhanced PCa growth (Supplementary Fig. 8c,d) at 19
weeks of age, increased Ki-67þ but decreased CC3þ expression
levels compared with Ptenpc / prostates (Fig. 5e–g). IHC
analysis revealed absence of pY-Stat3 and Stat3 expression in
Ptenpc / IL-6 / tumours (Supplementary Fig. 8e).
Intriguingly, in vivo blocking of IL-6/STAT3 signalling by the
JAK1/2 inhibitor ruxolitinib in human LNCaP xenografts showed
signiﬁcantly enhanced tumour size and weight (Fig. 6a,b). The
ruxolitinib-treated xenografts also had markedly increased
numbers of Ki-67þ cancer cells accompanied by a decrease in
STAT3 and p14ARF expression (Fig. 6c). Moreover, ruxolitinib
treatment of LNCaP cells signiﬁcantly promoted colony forma-
tion (Fig. 6d). Of note, LNCaP cells lack JAK1 expression and do
not respond to interferon signalling31. Moreover, STAT3 was
shown to be activated in xenografts of LNCaP cells, most likely
due to the sole action of JAK2 (refs 32,33). Ruxolitinib is a dual-
speciﬁc JAK1/2 kinase inhibitor and therefore, effects of
ruxolitinib on the LNCaP xenograft model are likely to be a
consequence of JAK2/STAT3 inhibition independent of IFN
gamma signalling.
Loss of STAT3 and ARF in PCa is associated with metastases.
The fact that activated STAT3 induces its own transcription34 led
us to measure IL-6 and STAT3 mRNA levels in primary human
tumours and to correlate them with clinical outcome. Using the
Taylor gene expression proﬁling data set (GSE21032)35, we
dichotomized samples based on the z-scores of IL-6 or STAT3
expression. Speciﬁcally for IL-6 expression, samples that had z-
scoreso 2 were deﬁned as low IL-6 and all others (z-
scores4 2) were used as a comparator for prognostic
signiﬁcance. Conversely, samples that had STAT3 z-scores42
were deﬁned as STAT3 high and all other samples (z-scoreso2)
were used as comparators. Time to biochemical recurrence (BCR)
was assessed as an indicator of individual prognosis. BCR was
deﬁned by an increase to 40.2 ngml 1 PSA in serum. Of note,
patients with low IL-6 expression levels showed a signiﬁcantly
higher risk of BCR compared with patients with high IL-6
expression (Fig. 7a). In line, patients with high Stat3 mRNA levels
demonstrate good prognosis. This may reﬂect a higher level of
senescence competence compared with patients with lower Stat3
mRNA levels (Fig. 7b).
We next tested whether expression of STAT3 and p14ARF can
serve as novel prognostic markers predicting the risk of BCR and
metastatic disease progression. STAT3 and p14ARF levels were
independently evaluated by ﬁve pathologists in 204 human PCa
specimens from patients who underwent radical prostatectomy.
Patient samples were categorized into low or high expression
groups based on staining intensities and number of positive cells
(Methods) using validated antibodies (Supplementary Fig. 9a,b).
Classiﬁcation was veriﬁed by quantitative histopathological image
analysis36 (Supplementary Fig. 10a). Indeed, increased Gleason
score (GSC) correlated with low STAT3 or p14ARF protein
expression levels. In addition, we found a strong direct correlation
between STAT3 and p14ARF in accordance with p14ARF being a
direct target of STAT3 (Fig. 7c,d). STAT3 expression was
signiﬁcantly decreased in PCa (GCSr7) compared with PIN
areas of 67 matched patient samples (Supplementary Fig. 10b,c).
Strikingly, both low STAT3 expression (Po0.007; log-rank test)
and low p14ARF (Po0.000001; log-rank test) expression were
associated with poor outcome (Fig. 7e,f). Moreover, combined loss
of p14ARF and STAT3 expression in tumours of PCa patients
predicted the worst outcome (P¼ 0.000007, log-rank test)
(Fig. 7g). Using multivariate analysis, we identiﬁed p14ARF as a
reliable, independent prognostic marker for PCa, which has a
twofold higher hazard ratio compared with GSC (Fig. 7h). In
accordance with the literature25,37, we found increased AR
expression in metastases compared with primary human PCa
(Supplementary Fig. 11a,b). IHC analysis of matched primary and
metastatic human PCa revealed signiﬁcant loss of PTEN
expression in metastatic PCa (Fig. 8a and Supplementary
Fig. 11c), suggesting an important role of PTEN loss in PCa
metastasis. PTEN levels showed no signiﬁcant correlation with
STAT3 or p14ARF protein expression in a cohort of4200 patients
(Supplementary Fig. 11d,e). Moreover, we demonstrated that loss
of STAT3 and/or p14ARF is associated with progression to
metastatic disease (Fig. 8b–d). This is supported by expression
data from matched primary and metastatic PCa samples
(Supplementary Fig. 12a–c), where in all seven cases a signiﬁcant
loss of STAT3 and p14ARF expression occurred in the metastases.
Current data suggest that PCa harbour common genomic and
epigenomic alterations38,39. We analysed large-scale human cancer
data sets (International Cancer Genome Consortium (ICGC) and
COSMIC databases) and the GEO methylation database40.
Surprisingly, we found mutations of STAT3 (2.5%) and CDKN2A
(2.3%) in a cohort of 529 patients with primary PCa (Fig. 8e). We
found ﬁve missense-, one nonsense- and several conservative
STAT3 mutations in primary PCa patients (Supplementary
Fig. 13a). STAT3 and/or CDKN2A were frequently deleted in
metastatic PCa (Fig. 8f and Supplementary Fig. 13b), which have
been conﬁrmed in an independent data set35 (Fig. 8g). Notably, in
66% of STAT3 deletions, PTEN was co-deleted in both metastases
data sets investigated (Fig. 8f,g). However, we neither detected
human IL-6 mutations nor methylation of STAT3 and CDKN2A
loci in primary and metastatic PCa (Supplementary Figs 13c,d and
Supplementary Figs 14a,b).
Discussion
Due to the lack of prognostic markers for risk stratiﬁcation, many
PCa patients suffer from overtreatment and a severely reduced
quality-of-life. Understanding the molecular genetics underlying
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PCa and the identiﬁcation of genetic and/or biochemical markers
predicting clinical outcome is therefore of high priority.
Our data reveal robust upregulation of the IL-6/Stat3 signalling
axis in a PCa mouse model as well as in patient specimens.
Loss of Stat3 or IL-6 accelerates the progression to metastatic
PCa; this stands in sharp contrast to the proposed oncogenic
function of IL-6/Stat3 signalling in PCa33,41,42. Moreover, there
are contradictory studies on the role of senescence in
tumorigenesis42–44. Whether these different ﬁndings are due to
the use of distinct mouse models, strains and species remains to
be addressed. Here we combine an array of experimental
approaches including in vivo models, mechanistic data with
comprehensive human pathological, molecular and genetic data
to underscore the tumour suppressive role of STAT3 (ref. 45).
Thereby we identify STAT3 and its transcriptional target ARF
as novel powerful prognostic markers for PCa patients. In PCa
and several other cancers, elevated serum IL-6 levels correlate
with a poor prognostic outcome for patients46. This sparked the
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development of IL-6 inhibitors to abrogate hyperactive IL-6/
STAT3 signalling. However, blocking IL-6/STAT3 signalling was
ineffective in patients with advanced PCa9,47, challenging this
oncogenic concept.
We show that loss of Stat3 accelerates malignant progression of
prostate tumours through abrogation of p19ARF expression, which
we identiﬁed as a novel direct Stat3 target gene. Several reports
have demonstrated that loss of Pten leads to increased senescence
associated with p53 stabilization triggered by p19ARF (refs 11,48).
Inactivation of Stat3 and Pten revealed striking similarities to
the malignant phenotype observed after deletion of Pten and p53
(ref. 11). Our model implicates high Stat3 and/or IL-6 levels in
senescence-competent PCa and therefore does not contradict
the general observation of high IL-6 and/or Stat3 expression in
many cancers. We show that impaired p19ARF expression
in Stat3-deﬁcient PCa is accompanied by loss of senescence. In
line with our data, concomitant loss of Pten and p19ARF in MEFs
resulted in bypass of senescence, induction of hyperproliferation
and oncogenic transformation11. Accordingly, overexpression of
p19ARF leads to p53-dependent cell growth arrest and induces
senescence49. However, systemic p19ARF deﬁciency in Ptenpc /
mice did not accelerate PCa or enhance p53 accumulation50,
which might be explained by inﬂammatory cytokines and/or
growth factors produced by the multiple tumours developing in
other organs51. Here we identiﬁed an unpredicted tumour
suppressor role for Stat3 signalling in PCa by its ability to
control the tumour suppressor ARF–Mdm2–p53 pathway in a
context-dependent manner. Therefore, we propose the STAT3–
ARF axis as a previously unknown safeguard mechanism against
malignant progression in PCa. Importantly we also demonstrate
that loss or inhibition of STAT3–ARF signalling enables tumour
progression and metastasis formation. This is reﬂected in patients
with PCa, since loss of STAT3 and/or p14ARF expression
signiﬁcantly correlates with poor prognosis in large
independent data sets. Therefore, our study identiﬁes STAT3
and ARF as potential novel prognostic markers predicting BCR-
free survival. The importance of the STAT3–ARF axis is
corroborated by the presence of STAT3 mutations in primary
PCa and frequent deletions of STAT3 and ARF in metastatic PCa.
The signiﬁcant loss of STAT3 and p14ARF expression from
matched primary and metastatic PCa samples underlines the
relevance of our ﬁndings.
Interestingly, loss of PTEN expression in primary human PCa
did not correlate with overall survival52 and could not predict
PCa-speciﬁc death53. Moreover, heterozygous PTEN deletions far
outnumber homozygous deletions in primary human PCa54 and
we show here that PTEN is mutated or lost only in a small subset
(4.7%) of a large cohort of patients with primary PCa. However,
PTEN is lost in450% of human PCa metastases55,35, suggesting
an important role for PTEN in this process. Finally, we show in
our study that STAT3 is co-deleted with PTEN in 66% of human
PCa metastases in two independent data sets. Since PTEN is
mutated or lost in only a minor fraction of primary PCa, other
aberrations must occur (oncogene induction or loss of tumour
suppressor function) to activate STAT3 and ARF to induce
senescence in human cancers. Indeed, several studies indicate that
different aberrations can lead to induction of senescence in
human cancers48,56.
Many human PCa cases are diagnosed with low GSCs, which
are of clinical low risk. Only a minority of these tumours will
progress to aggressive lethal PCa. We show that ARF is an
independent prognostic marker with a twofold higher hazard
ratio compared with GSC (Fig. 7h). This will enable signiﬁcantly
improved stratiﬁcation of low risk PCa patients into active
surveillance, avoiding severe side effects such as incontinence
and/or impotence. Together with a previously deﬁned four-gene
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signature of aggressive tumours, including PTEN, SMAD4,
CCND1 and SPP1 (ref. 16), determination of STAT3 and ARF
expression could signiﬁcantly improve the selection of patients
with high risk PCa for personalized anti-cancer treatment.
We have uncovered a paradigm shift in understanding the key
function of STAT3 in tumorigenicity and metastatic progression
in PCa. Therefore, our results call for cautious use of anti-IL-6-
STAT3 signalling blockers in the treatment of PCa as this may
turn low-grade tumours into highly malignant cancers by loss of
senescence controlled by the STAT3–ARF axis. As IL-6/STAT3
signalling blockers are successful in the treatment of
chronic inﬂammatory or autoimmune diseases, their inﬂuence
on PCa development needs to be carefully evaluated in
future studies. Reactivating the IL-6/STAT3/ARF-dependent
senescence pathway57 might be a promising strategy for PCa
therapy via downregulation of Mdm2 (ref. 58) or p53 induction59.
Alternatively, triggering ARF–p53-independent cellular
senescence by a small molecule inhibitor60, could be beneﬁcial
for PCa patients in whom other therapies have failed.
Methods
Generation of transgenic mice. PtenloxP/loxP mice crossed with male PB-Cre4
transgenic mice were generated as described previously13,61. To generate prostate-
speciﬁc deletion of Pten and IL-6, we took advantage of IL-6 / mice30. In a
similar strategy, mice carrying Stat3loxP/loxP 62 were maintained and crossed with
PB-Cre4 PtenloxP/loxP transgenic mice. All mice were maintained on a C57BL/6 and
Sv/129 mixed genetic background. Animal experiments were reviewed and
approved by the Austrian ministry authorities and conducted according to relevant
regulatory standards (BMWF-66.009/0281-I/3b/2012).
Immunohistochemistry and histological analysis. Immunohistochemistry and
haematoxilin/eosin staining was performed with formalin-ﬁxed parafﬁn-embedded
(FFPE) tissue using standard protocols using consecutive sections. The following
antibodies were used for immunohistochemistry: pY-Stat3 (1:80 dilution; Cell Sig-
naling, #9145), pS-Stat3 (1:80; Cell Signaling, #9134), Stat3 (1:200 dilution; SCBT, sc-
7179), p-Akt (1:80 dilution; Cell Signaling, #4060), Akt (1:100 dilution; Cell Sig-
naling, #4691), p53 (1:50 dilution; Calbiochem, pAb421 ), p19ARF (1:200 dilution;
Abcam, ab-80), p14ARF (1:100 dilution; SCBT, sc-8340), p21 (1:100 dilution; SCBT,
sc-397), PML (1:100 dilution; SCBT, sc-966), Ki-67 (1:1,000 dilution; Novocastra;
NCL-KI-67-P) and Cleaved Caspase 3 (1:200 dilution; Cell Signaling, #9661) and
ISG15 (1:30; Abcam, 131119), AR (1:300; SCBT, sc-816). Staining for SA--Gal
activity was performed according to the manufacturer’s protocol (Cell Signaling,
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#9860). We used PTEN63 and AR (1:250; DAKO, AR441)64 antibodies validated for
FFPE IHC. The STAT3 antibody was validated using SW620 colon cancer xenografts
with shRNA-mediated knockdown (Supplementary Fig. 9b). The speciﬁcity of
p14ARF antibody was validated using the human melanoma cell lines65 VM-28 (WT
for p14ARF) and VM-7 (deletion at the p14ARF locus).
All images were taken with a Zeiss AxioImager Z1, and quantiﬁcation was
performed with HistoQuest (TissueGnostics GmbH, Vienna, Austria,
www.tissuegnostics.com) as described in detail in (ref. 36). In brief, haematoxylin
staining was used for cell identiﬁcation. The range of intensities of the master
marker (haematoxylin) and the immunohistochemical stainings were set by
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autodetection of the software. All images were analysed with the identical settings
after adjustments. The results are visualized in dot plot scattergrams and/or
histograms. Cut-offs (to differentiate between positive and negative cells) and gates
(to accentuate between cell populations) were set in the dot blots. For statistical
analysis, the raw data were imported into GraphPad Prism 6 (GraphPad Software),
analysed for signiﬁcance and processed for data output. All images were taken with
the same exposure time, signal ampliﬁcation and objectives.
Western blot analysis. For protein expression analysis by western blot, frozen
tissue samples and cell lysates were prepared as described16. Blots were blocked
with 5% BSA or 5% non-fat dry milk in 1TBS/0.1% Tween-20 for 1 h and
incubated with the primary antibody overnight at 4 C. Primary antibodies were
reactive to pY-Stat3 (1:500 dilution), pS-Stat3 (1:1,000 dilution), Stat3 (1:1,000
dilution; Cell Signaling, #9132), p19ARF (1:1,000 dilution), p53 (1:1,000 dilution;
Cell Signaling, #2524), p21 (1:500 dilution), b-actin (1:5,000 dilution; Sigma-
Aldrich, A5316), p-Akt (1:1,000 dilution), Akt (1:2,000 dilution ), AR (1:1,000
dilution), GAPDH (1:5,000 dilution; Cell Signaling, #2118), Pan-Cytokeratin (1,000
dilution; Abcam, Ab6401), Mdm2 (1:500 dilution; Millipore, 04-1530), PML (1:500
dilution; Millipore, MAB3738) and GAPDH (1:25,000; Trevigen, 2275-PC-100).
Supplementary Figures 15–19 show uncropped immunoblots.
RNA and qRT–PCR. Total RNA was isolated using Trizol (Invitrogen) according to
the manufacturer’s instructions. For quantitative reverse transcription PCR
(qRT–PCR) analysis, 1mg of total RNA was reverse transcribed to cDNA using the
Transcriptor First-Strand cDNA Synthesis kit (Fermentas). qRT–PCR was per-
formed in triplicate with aa MxPro3000 and SYBR GreenERqPCR mix (Invitrogen).
Real-time monitoring of PCR ampliﬁcation was performed using the LightCycler
480 detection system (Roche). The relative amount of speciﬁc mRNA was nor-
malized to b-actin in each sample. Primer pairs are listed in Supplementary Table 3.
Cell culture. Primary WT and Stat3-null MEF were isolated by trypsin treatment
of individual littermate E13.5 embryos from a cross of Stat3þ / heterozygous
mice. Stat3þ / mice were generated from conditional Stat3þ /ﬂ mice66 by deletion
of the conditional allele in vivo using Mox2-Cre. Cells were ampliﬁed and used in
experiments starting at passage 2. Stat3 / MEFs were grown in DMEM
supplemented with 10% FBS, 2mM L-Glutamine, 0.1mM NEAA, 20mM HEPES
and pen/strep using standard techniques. Stat3C/þ and Stat3C/C MEFs were
generously provided by Valeria Poli28. For in vitro cultures LNCaP, RWPE-1 and
PC3 were cultured under standard conditions.
Generation of primary mouse prostate cell lines. Dissected prostate tissue from
WT and Ptenpc / mice at 19 weeks of age was cut into pieces of 0.2mm, plated
in tissue culture dishes coated with type I collagen (BD Pharmingen) and supplied
with a minimal amount of epithelial growth medium containing 1% FBS serum.
After 24 and 48 h, more medium was added. After an additional 24–72 h, cells
began to grow out from the prostate tissue. Clean epithelial cell lines were obtained
by removing the unwanted cell type with a cell scraper or pipette tip. Cells were
passaged using Accutase (PAA, L11-00). For the generation of cell lines, cells were
passaged until they survived crisis and only cells with typical epithelial morphology
were maintained. WT and Ptenpc / prostate cell lines were established and
maintained in DMEM/F12 (Invitrogen, 3133095) plus 10% foetal bovine serum
(PAA, A15-101), 25mgml 1 bovine pituitary extract (Invitrogen, 13028014),
5mgml 1 EGF (Peprotech, 315-09), insulin/transferrin/selenite (Invitrogen,
41400-045), pen/strep (PAA, 30-002-CI), cholera toxin (Sigma-Aldrich, C8052-
5MG) and ciproﬂoxacin (Sigma-Aldrich, 17580-5G). Prostate tumour epithelial cell
lines expressed the epithelial marker Pan-Cytokeratin detected by immuno-
ﬂuorescence and western blot analysis. Pten deletion was conﬁrmed by PCR and
western blot analysis.
Human tissue microarray. The human tissue arrays representing a panel of 204
patient samples were obtained from the Institute of Pathology, Tuebingen,
Germany and from the Clinical Institute of Pathology (CIP) of the Medical
University of Vienna (MUW), Vienna, Austria. The cohort contains tumour
material from PCa patients who consecutively underwent radical prostatectomy at
the University Hospital of Tuebingen or the University Hospital of the MUW. Each
PCa specimen was represented by two cores on tissue microarrays (TMA). From
the CIP of the MUW, we furthermore obtained 41 PCa and 23 metastasis FFPE
patient samples. In addition, we include FFPE material from 67 matched patient
samples with PIN and PCa (GSCr7), as well as 7 matched patient samples with
primary PCa and PCa metastases, all from the CIP, MUW. The FFPE tissue blocks
were sectioned as 3-mm-thick sections mounted on slides and stained with hae-
matoxylin and eosin. Subsequently, the area of cancer was marked by a pathologist
(S.P.). Cores, each of up to 0.6mm in diameter, were taken from the corresponding
donor block and placed into a TMA recipient block using a semiautomatic tissue
arrayer (Beecher Instruments). Tissue sections (3-mm thick) were placed onto
superfrost slides. IBM SPSS Statistics 20 (IBM) was used for statistical analysis. For
determination of time to BCR, which is deﬁned by an increase to 40.2 ngml 1
PSA in serum, a log-rank (Mantel–Cox) test was used to test signiﬁcance. The
hazard ratio and its conﬁdence interval were calculated using the Mantel–Haenszel
method. All the human samples for TMA and their use in this study were approved
by the Research Ethics Committee of the Medical University Vienna, Austria
(1753/2014) and by the Research Ethics Committee for Germany (395/2008BO1)
(Bonn, Germany).
Statistical analyses. Data were analysed using GraphPad Prism 6 software. For
comparing two groups unpaired Students t-test and for comparing more than two
groups Tukey´s post hoc test was used. Fisher’s exact test was employed when
differences in distributions within groups were monitored. For Kaplan–Meier
analysis and log-rank statistical evaluation of time to BCR, as well as evaluation of
prognostic power in univariate and multivariate analysis, we used the IBM SPSS
version 22 programme. To analyse Affymetrix SNP Chip 6.0 primary data, we used
the AGCCytoScan Software together with the Chromosome Analysis Suite 3.0
(both Affymetrix), and deletions4200 kb were considered signiﬁcant. For analysis
of mutations in primary PCa, we used the ICGC (www.icgc.org).
ELISA. For the detection of soluble sIL-6R in sera of mice, the samples were diluted
1:15 in 1% BSA–PBS. The ELISA was performed as described67. In brief, microtiter
plates (Greiner Microlon) were coated with anti-murine IL-6-R pAB AF1830
(0.8 mgml 1; R&D Systems) in PBS. After blocking, 100ml aliquots of cell lysates
or culture supernatants were added. IL-6R bound to the plate was detected by
biotinylated goat anti-mouse IL-6-R pAB BAF1830 (working concentration,
0.2 mgml 1; R&D Systems) followed by streptavidin–horseradish peroxidase
(R&D Systems). The enzymatic reaction was performed with soluble peroxidase
substrate (BM blue POD from Roche) at 37 C and the absorbance was read at
450 nm on a SLT Rainbow plate reader (Tecan). For the detection of murine IL-6 in
sera of mice, the samples were diluted 1:3 with 1% BSA–PBS.
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